OLANZAPINE SANDOZ ODT 15 olanzapine 15mg orally disintegrating tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

olanzapine sandoz odt 15 olanzapine 15mg orally disintegrating tablet blister pack

sandoz pty ltd - olanzapine, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: purified talc; crospovidone; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; hyprolose; flavour - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

IRBESARTAN/HCT SANDOZ  300/25 irbesartan 300 mg/hydrochlorothiazide 25 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

irbesartan/hct sandoz 300/25 irbesartan 300 mg/hydrochlorothiazide 25 mg film-coated tablet blister pack

sandoz pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: hypromellose; iron oxide black; macrogol 6000; colloidal anhydrous silica; lactose monohydrate; titanium dioxide; croscarmellose sodium; purified talc; microcrystalline cellulose; hyprolose; iron oxide red; magnesium stearate - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

IRBESARTAN/HCT SANDOZ  150/12.5 irbesartan 150 mg/hydrochlorothiazide 12.5 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

irbesartan/hct sandoz 150/12.5 irbesartan 150 mg/hydrochlorothiazide 12.5 mg film-coated tablet blister pack

sandoz pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: purified talc; hypromellose; lactose monohydrate; iron oxide red; titanium dioxide; microcrystalline cellulose; croscarmellose sodium; iron oxide yellow; macrogol 6000; hyprolose; magnesium stearate; colloidal anhydrous silica - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

IRBESARTAN/HCT SANDOZ  300/12.5 irbesartan 300 mg/hydrochlorothiazide 12.5 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

irbesartan/hct sandoz 300/12.5 irbesartan 300 mg/hydrochlorothiazide 12.5 mg film-coated tablet blister pack

sandoz pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; lactose monohydrate; hyprolose; titanium dioxide; croscarmellose sodium; colloidal anhydrous silica; macrogol 6000; purified talc; microcrystalline cellulose; iron oxide red; iron oxide yellow - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

EXEMESTANE SANDOZ Australia - English - Department of Health (Therapeutic Goods Administration)

exemestane sandoz

sandoz pty ltd - exemestane, quantity: 25 mg - tablet, film coated - excipient ingredients: mannitol; polysorbate 80; microcrystalline cellulose; hypromellose; macrogol 400; colloidal anhydrous silica; titanium dioxide; magnesium stearate; sodium starch glycollate type a; crospovidone - exemestane sandoz is indicated for the sequential adjuvant treatment of oestrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy.,exemestane sandoz is indicated for the treatment of oestrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.